RxDoctor Payments Data

Lailae Furutan, MD

Internal Medicine · Highland, CANPI 1912952771

Payments from drug & device makers

$515in general payments, 2019–2025

Across 36 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$130
  • Pfizer$113
  • AstraZeneca$80
  • Kowa Pharmaceuticals America, Inc.$36
  • GSK$35
  • Amgen$25
  • plus $96 from 6 others

What the payments were for

  • Food & beverage$515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$515 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$10,320
Medicare patients
61
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$79,138
OzempicSemaglutide34$44,999
TrulicityDulaglutide35$42,868
FarxigaDapagliflozin Propanediol51$33,650
JanuviaSitagliptin Phosphate27$27,100
XareltoRivaroxaban24$20,342
JardianceEmpagliflozin16$16,705
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$14,589
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,411
SynthroidLevothyroxine Sodium69$4,672
SymbicortBudesonide/Formoterol Fumarate15$3,879
Levothyroxine Sodium331$3,705
Gabapentin185$3,566
Wixela InhubFluticasone Propion/Salmeterol22$2,821
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$79,13882 claims
AstraZenecaFarxiga, Symbicort$80$37,52966 claims
MerckJanuvia$17$27,10027 claims
Johnson & JohnsonXarelto$17$20,34224 claims
GSKTrelegy Ellipta$35$12,41120 claims
AbbVieSynthroid$130$4,67269 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Highland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →